title: The FDA, bridging data, and hepatitis C.
authors: Michael W
authors: MW
authors: Fried
authors: Donald M
authors: DM
authors: Jensen
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D017277:Drug Approval / Q000379:methods*; D016903:Drug Monitoring / Q000379:methods*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use*; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline